Your browser doesn't support javascript.
loading
Early skeletal muscle loss in adolescent and young adult cancer patients treated with anthracycline chemotherapy.
Wooten, Savannah V; Wang, Fei; Roth, Michael E; Liu, Guanshu; Livingston, J Andrew; Amini, Behrang; Gilchrist, Susan C; Hildebrandt, Michelle; Kleinerman, Eugenie S.
Afiliación
  • Wooten SV; Department of Pediatrics Research, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Wang F; Department of Pediatrics Research, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Roth ME; Department of Pediatrics Research, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Liu G; Department of Pediatrics Research, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Livingston JA; Department of Pediatrics Research, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Amini B; Department of Sarcoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Gilchrist SC; Department of Musculoskeletal Imaging, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Hildebrandt M; Department of Cardiology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
  • Kleinerman ES; Department of Lymphoma/Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Cancer Med ; 12(22): 20798-20809, 2023 11.
Article en En | MEDLINE | ID: mdl-37902220
BACKGROUND: Early skeletal muscle loss has been observed in adolescent and young adult (AYA) sarcoma patients undergoing treatment. Identification of individuals within the AYA populace that are at greatest risk of anthracycline-induced skeletal muscle loss is unknown. Moreover, investigations which seek out underlying causes of skeletal muscle degradation during chemotherapy are critical for understanding, preventing, and reducing chronic health conditions associated with poor skeletal muscle status. METHODS: Computed tomography (CT) scans were used to investigate changes in skeletal muscle of 153 AYA sarcoma and Hodgkin lymphoma patients at thoracic vertebra 4 after anthracycline treatment. Images were examined at three time points during the first year of treatment. In parallel, we used translational juvenile mouse models to assess the impact of doxorubicin (DOX) in the soleus and gastrocnemius on muscle wasting. RESULTS: Significant reductions in total skeletal muscle index and density were seen after chemotherapy in AYA cancer patients (p < 0.01 & p = 0.04, respectively). The severity of skeletal muscle loss varied by subgroup (i.e., cancer type, sex, and treatment). Murine models demonstrated a reduction in skeletal muscle fiber cross-sectional area, increased apoptosis and collagen volume for both the soleus and gastrocnemius after DOX treatment (all p < 0.05). After DOX, hindlimb skeletal muscle blood flow was significantly reduced (p < 0.01). CONCLUSION: Significant skeletal muscle loss is experienced early during treatment in AYA cancer patients. Reductions in skeletal muscle blood flow may be a key contributing factor to anthracycline doxorubicin induced skeletal muscle loss.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sarcoma / Enfermedad de Hodgkin Límite: Adolescent / Adult / Animals / Humans Idioma: En Revista: Cancer Med Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sarcoma / Enfermedad de Hodgkin Límite: Adolescent / Adult / Animals / Humans Idioma: En Revista: Cancer Med Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos